During the pathogenesis of Parkinson’s disease (PD), α-synuclein pathology may originate in peripheral organs and spread to the CNS. Using human tissue samples and multiple approaches in mouse ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Understanding the pathogenesis of LID has contributed ... of dyskinesia as a motor complication in the course of Parkinson's disease (PD) includes a spectrum of involuntary movements schematically ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Clinical diagnosis of Parkinson's disease (PD) could be performed in ... and serotoninergic systems has been implicated in the pathogenesis of depression in PD. They have been associated with ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.“This ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...